CARI Health

It's really all about the team.

We have assembled an amazing team of scientists, clinicians and innovators in our quest to bring
remote medication monitoring to the world.

Patrik Schmidle

Patrik Schmidle​

Chief Executive Officer

Dr. Foster Carr

Foster Carr, MD

Chief Medical Officer

Aditya Mandapaka

Adi Mandapaka

Chief Technology Officer

Advisory Board

We have assembled an amazing board of advisors with valuable clinical, scientific, regulatory,  technical and commercial expertise.     

Patrik Schmidle

Patrik Schmidle​

Chief Executive Officer

For the first part of his career Patrik worked in various start-ups, mid-sized, privately-held companies as well as large, publicly-traded companies, primarily in the B2B software and market research industries where client lists included many leading technology companies. He took on as many different roles as possible to learn about all aspects of business, always with the goal becoming an entrepreneur. After being part of six acquisitions as an employee, he was inspired to found CARI Health after watching a close family member’s struggle with opioids. Since then, he’s been leading a team of clinicians, bio-chemical and electrical engineers on a mission to build a company that will have a positive and lasting impact on the opioid crisis.

Dr. Foster Carr

Foster Carr MD

Chief Medical Officer

Dr. Carr is a Harvard and Stanford trained physician-entrepreneur.  He entered the field of addiction medicine in 2015 and serves as the Medical Director of an Outpatient Treatment Program for opioid use disorder.  His prior training in Biochemical Sciences at Harvard, medical school trainings in medical informatics at Stanford Medical School, and Internal Medicine trainings at UCSF/UCSD created the basis for his pursuit of the first website for internet-based telemedicine in the United States.  In the spring of 1999 he was awarded the Cybervision Award for the Homecare Extranet from the US Department of Health and Human Services.  Subsequently he built a protocol engine for asynchronous telemedicine as the cofounder of  Gogohealth LLC .  His vision and clinical experience significantly contributed to the methadone use case for the CARI Health electrochemical sensor. 

Aditya Mandapaka

Adi Mandapaka

Chief Technology Officer

Adi Mandapaka is a Technology/Product Developer and Entrepreneur in the Wearables, Medical Devices and Digital Health spaces.  His early career was spent learning engineering for scale at large public technology companies, before pivoting to work on his true passion – the application of technology towards improved, inexpensive health and wellness for all.  His last few years have been spent involved with CGM, Wearable and Digital Health companies, trying to move the needle on better, cheaper and more connected healthcare across the globe.  Adi joined the team at CARI Health as CTO to work on creating the world’s first Wearable Remote Medication Monitor.

Laurie Russell

Laurie Russell

Operations Director

Laurie is an innovative executive with expertise implementing leading edge strategies to streamline business operations and increase profitability. She has experience in both the corporate and non-profit sectors not only in project management but also marketing, and business development.  She oversees the daily operations at CARI.

Gioia Messinger

Gioia Messinger

Board Director

Gioia Messinger brings more than 30 years of high technology executive experience, with over two decades focused on consumer electronics, Internet of Things (IoT), robotics/artificial intelligence (AI) and digital health as Founder/CEO, board member, interim executive and venture capital advisor.  Ms. Messinger is the founder and Principal of LinkedObjects, Inc., a strategic advisory services business focused on digital transformation brought about by AI and IoT.  She currently is an advisor to several start-ups and serves on the board of One Stop Systems (NASDAQ:OSS) and Indyme Solutions.  Ms. Messinger obtained her MBA from the Paul Merage School of Business at the University of California, Irvine and her B.S./M.A. in Computer Engineering from University of California, San Diego.  She’s an inventor on 11 patents.

Charles Patton

Charles Patton

Board Director

Charles currently is a private investor and serves on both for-profit and not-for-profit boards.  Prior, he was the lead healthcare partner at Oak Hill Capital Partners, a middle market private equity firm.   He has been an investor in Accolade, Accretive Healthcare, AccentCare, Jazz Pharmaceuticals, and Align Technology among others. Other early-stage investments include Village Practice Management, Vera Whole Health, Stability Health, and Recovery One.   Not-for-profit activities include serving on the boards of Bay Area Center for Arts and Technology (BAYCAT), Verity Health, the Ralph Lauren Center for Cancer Care and Prevention, and Matters Athletic.  Mr. Patton earned a B.S. degree from the University of California, Berkeley and an M.B.A. from Harvard Business School. 

Drew Hall

Drew Hall, Ph.D.

Technical Advisor

Dr. Hall received a B.S. degree in computer engineering with honors from the University of Nevada, Las Vegas, in 2005, along with M.S. and Ph.D. degrees in electrical engineering from Stanford University in 2008 and 2012, respectively. In 2013, he joined the Jacobs School of Engineering at the University of California, San Diego, where he is currently an associate professor in the Department of Electrical and Computer Engineering and an affiliate professor in the Department of Bioengineering. He is an expert in biosensors, bioelectronics, and analog integrated circuit design.

Natasia Courchesne

Natasia Courchesne-Krak, Ph.D.

Clinical Advisor

Over the past 10 years, Dr. Courchesne-Krak has worked in the fields of psychiatric epidemiology, neuroscience, and genetics. She integrates state-of-the art bioinformatics approaches with small- and large-scale population datasets to advance our understanding of substance use disorders (e.g., opioids, alcohol, stimulants, cannabis) and patient health. Dr. Courchesne-Krak has investigated the impact of substance use on neurodevelopment, healthcare service utilization, morbidity, and mortality among children, adults, and pregnant women. She is passionate about novel treatment strategies designed to improve patient care and health outcomes.

Jon S. Wilensky

Jon S. Wilensky, MD

Surgical & Technical Consultant

Dr. Jon Wilensky is a Board Certified Plastic and Reconstructive Surgeon, whose practice is exclusively dedicated to implantable, injectable, and wearable biotechnology. He has served as a Surgical and Technical Consultant to multiple industry partners including diabetes pioneers GlySens and ViaCyte. He is also an experienced Founder and Bioentrepreneur, and holds an MBA from the Rady School of Management. He is on the active Medical Staffs of Scripps Health and Palomar Health, the latter a member of the Mayo Clinic Care Network. His passion is to radically solve the biggest problems in healthcare with disruptive, breakthrough technologies.

Mark Prausnitz

Mark Prausnitz, Ph.D.

Technical Advisor

Mark Prausnitz is Regents’ Professor and J. Erskine Love, Jr. Chair of Chemical & Biomolecular Engineering at the Georgia Institute of Technology. He earned a BS degree from Stanford University and PhD degree from MIT, both in chemical engineering. Dr. Prausnitz and colleagues carry out research on drug delivery using microneedles, lasers, ionic liquids and other microdevices for transdermal, ocular and intracellular delivery of drugs and vaccines. Dr. Prausnitz teaches courses on engineering calculations and pharmaceuticals. He has published more than 300 journal articles, invented almost 70 US patents, and has co-founded seven start-up companies based on microneedle technologies.

Brenda Davis

Brenda Davis, MSW

Advisory Board

Brenda J. Davis currently holds a position as the Patient Advocate Manager at the Addiction Institute of Mount Sinai at Beth Israel’s OTP and inpatient division. As the patient advocate for this premier New York institution, Ms. Davis provides crisis intervention, conflict resolution and supportive services to all the patients in need of services. Ms. Davis graduated Magna Cum Laude from the Touro School of Social Work where she was also the recipient of the Tikkun Olam award. She serves on the board of directors for the National Alliance for Medication Assisted Recovery (NAMA-R) and Stop Stigma Now. She has devoted many years of direct services to individuals, and technical assistance to organizations supporting individuals in need of treatment and recovery, as well efforts to eliminate substance use related stigma. Ms. Davis’ own history of long-term sustained recovery after many years of opioid use along with her educational achievements uniquely qualify her to understand the importance of treatment from a patient and provider perspective.
Carla Marienfield

Carla Marienfeld, MD

Clinical Advisor

Carla Marienfeld, MD, DFAPA, FASAM is board-certified in psychiatry, addiction psychiatry, and addiction medicine, and she is a Clinical Professor at the University of California San Diego. She edited two books:  Motivational Interviewing for Clinical Practice and Absolute Addiction Psychiatry Review:  An essential board exam study guide. She has been highly involved in education of colleagues and trainees, and she is the fellowship director for the UCSD Addiction Psychiatry Fellowship. Dr. Marienfeld completed a fellowship in addiction psychiatry and residency training in psychiatry at Yale, and her medical degree with honors is from Baylor College of Medicine in Houston.

Ed Kopetsky

Ed Kopetsky, MS

Advisory Board

Ed Kopetsky, former Senior Vice President and Chief Information Officer of Stanford Children’s Health is an accomplished healthcare executive with expertise in integrated healthcare systems, information technology, operations and cost improvement, digital transformation and consulting. Since joining Stanford Children’s Health in 2009, Ed has led large-scale changes in enterprise systems and customer service. Stanford Children’s Health and the Information Services team Ed led have received numerous industry accolades for being in the forefront leveraging health information technology and analytics to improve patient care. The health system received the international Healthcare Information and Management Systems Society (HIMSS) Davies Award in 2017 for its leading-edge use of health IT to substantially improve clinical care delivery, patient outcomes and population health. Ed also received the Distinguished Achievement Award from the University of Wisconsin College of Engineering for integrating Sharp Healthcare consisting of 7 hospitals and over 2,000 physicians. He has contributed to numerous professional organizations, including serving as a founding member and Board Chair for the College of Healthcare Information Management Executives (CHIME). Ed has served on multiple industry advisory boards including Dell, Hewlett-Packard, Encore, Next Wave Health Advisors, and CHESS Health. Following a family tragedy, in 2018 Ed co-founded and continues to co-chair the CHIME Opioid Task Force helping healthcare organizations confront the national opioid crisis. Ed earned his bachelor’s and master’s degrees in industrial and systems engineering from the University of Wisconsin-Madison.
Ken Stroller

Ken Stoller, MD

Advisory Board

Dr. Kenneth Stoller is a Professor of Clinical Psychiatry and Behavioral Sciences at Johns Hopkins University, where he directs the outpatient addiction treatment center at Johns Hopkins Hospital in Baltimore, MD. He is also Medical Director, Behavioral Health for Johns Hopkins Health Plans. His area of practice is the treatment of, and clinical research involving, substance use problems, particularly those involving pharmacotherapies for opioid use disorder. His work has focused cost/economic issues as they relate to drug addiction and treatment, enhancing adherence and retention, and integrating treatment of co-occurring psychiatric, somatic, pain and substance use disorders. He has also focused on fostering policies and initiatives applied in managed care settings to improve health outcomes and control costs.
Nicholas Tatonetti

Nicholas Tatonetti, Ph.D.

Advisory Board

Dr. Nicholas Tatonetti is Vice Chair of Operations in the Department of Computational Biomedicine and Associate Director of Computational Oncology in the Cancer Center at Cedars-Sinai Medical Center. He received his PhD from Stanford University where he focused on the development of novel statistical and computational methods for observational data mining. Over the past 14 years, he has applied these methods to drug safety surveillance and the discovery of dangerous adverse drug effects and has identified and validated previously unknown serious drug-drug interactions. His lab at Cedars-Sinai is focused on using massive-scale real clinical and molecular data for making robust and validated scientific discoveries, with a particular focus on detecting, explaining, and validating drug effects and drug interactions. Dr. Tatonetti has published over 130 peer-reviewed scientific publications across medicine, systems biology, machine learning, and bioinformatics. He is passionate about the integration of real-world data (such as those stored in the electronic health records) and high-dimensional biological data (captured using next-generation sequencing, high-throughput screening, and other “omics” technologies) to reimagine and rescale the scientific method.
Robert Kent

Robert Kent, JD

Advisory Board

Robert A. Kent is the President of Kent Strategic Advisors, a consulting firm focused on drug policy and assisting stakeholders with making treating and recovery more accessible. Mr. Kent most recently served as General Counsel with the Office of National Drug Control Policy (ONDCP), providing overall legal support to all components of ONDCP and assisting with the development of the 2022 National Drug Control Strategy. He previously served as the General Counsel for the New York State Office of Addiction Services and Supports (OASAS). Robert led the OASAS efforts to implement New York State’s Heroin and Opioid Task Force recommendations, including the Combat Addiction/Heroin Campaign, the Federal Opioid Targeted Grant program, and Medicaid Redesign Team initiatives including implementation of historic legislation to increase access to treatment, including harm reduction services. Mr. Kent is a graduate of the Syracuse University College of Law.
Robert Sherrick

Robert Sherrick, MD

Advisory Board

Dr. Robert Sherrick, MD, FASAM, is Chief Science Officer for Community Medical Services, a company that serves patients through over 70 Opioid Treatment Programs in 12 states. He has extensive experience treating all forms of Substance Use Disorders and dual diagnosis patients in both inpatient and outpatient settings. Dr. Sherrick has been providing Medication Assisted Treatment for Opioid Use Disorder since 2003, initially in an office setting using buprenorphine and subsequently with methadone in Opioid Treatment Programs. He established a state-wide buprenorphine treatment program for VA Montana with extensive use of telemedicine. He is board certified in Internal Medicine as well as Addiction Medicine through the American Board of Preventative Medicine. He is immediate Past President of the Northwest Chapter of the American Society of Addiction Medicine, a member of the Montana Medical Association, past Treasurer, and participates on the Substance Use Disorder committee.
Murray A. Reicher

Murray A. Reicher MD

Business Advisor

Bio coming soon!

Steven Shoptaw

Steven Shoptaw, Ph.D.

Clinical Advisor

Steven Shoptaw, Ph.D., is a licensed psychologist and the Center Director for the Center for HIV Identification, Prevention and Treatment Services (CHIPTS). He is Professor in the UCLA Departments of Family Medicine and Psychiatry and Biobehavioral Sciences and Vice Chair of Research in Family Medicine. Dr. Shoptaw energetically maintains research, clinical and policy efforts to bring novel and high impact solutions to delivering culturally competent care for persons affected by addictions and HIV. This often means developing innovative solutions that address consistent barriers to accessing structural and social determinants of health faced by people living with these interwoven health problems. He is active within the Los Angeles County area in working with policymakers, scientists and agency leaders to develop and evaluate initiatives to optimize impacts of HIV prevention and addiction investments. In addition to his extensive research portfolio, Dr. Shoptaw maintains a limited clinical psychology practice at UCLA, treating patients with severe substance use and mental health disorders.
Rajesh Seenivasan

Rajesh Seenivasan, Ph.D.

Research Scientist

Dr. Seenivasan received his Ph.D. in Chemistry from MaduraiKamaraj University, Tamil Nadu, India. As a Postdoc at the University of Wisconsin – Madison as well as UC San Diego, Dr. Seenivasan performed the multidisciplinary innovative research in the (bio)electroanalytical and surface chemistry field focusing on scalable point-of-care sensor/biosensor development.

Torsten Fiebig

Torsten Fiebig, Ph.D.

Chief Science Officer

Dr. Fiebig is a CalTech trained chemist and entrepreneur who straddles the line between academia and private industry. He has extensive expertise in analytical and biophysical chemistry, in addition to having founded several businesses. Dr. Fiebig received his Ph.D. in chemistry at the Max Planck Institute for Biophysical Chemistry, Germany.